Results
1 -
10 of
12Targeting Cyclin-Dependent Kinases with Small Molecule Inhibitors, Checkpoint Controls and Targets in Cancer Therapy New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer, Archives of Gynecology and Obstetrics Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon???) and ON013105, for Brain Tumor Chemotherapy, Pharmaceutical Research Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?, Targeted Oncology Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care, Blood Cancer Journal Zweitlinientherapie bei MDS, Im Focus Onkologie Vorteil nur in bestimmten Subgruppen?, Info Onkologie Vorteil nur f??r bestimmte Subgruppen?, Info Onkologie Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer, Current Oncology Reports Signal transduction inhibitors in treatment of myelodysplastic syndromes, Journal of Hematology & Oncology